BIOLOGICAL DYNAMICS
Company Snapshot
Company Overview
Biological Dynamics is developing a suite of novel assays for pharmaceutical applications, with an initial focus on detecting DNA and EV (extracellular vesicles)-associated biomarkers and liquid biopsy panels. These assays are developed using Verita, the company’s proprietary lab-on-a-chip biomarker isolation platform that isolates DNA and EVs from plasma and serum without needing pre-processing of samples.
The company’s lead product is OncoState IO assay, which measures the concentration of cfDNA in the plasma of patients with advanced NSCLC and who are undergoing treatments with advanced immune-oncology regimens. The system is marketed as an RUO and consists of a disposable cartridge and an automated benchtop analyzer. Each cartridge has eight independent arrays and can accommodate up to eight samples per run. The analyzer applies thermal, fluidics, optical, and electrical effects, and software to isolate, detect and quantify the cfDNA.
In January 2020, Biological Dynamics partnered with Microsoft’s One Commercial Partner (OCP) program with a goal of helping to strengthen its adoption of raw sample biomarker technology among Microsoft’s Life Sciences partners and customers.
BIOLOGICAL DYNAMICS In News
Company's Business Segments
- Product : ExoVerita Pro Platform, Verita Technology
- Service : Exosome Isolation and Analysis Services
Applications/End User Industries
- Healthcare
- Oncology
- Pharmaceuticals
- Biotechnology
- Academic Research
